rs1800471 — TGFB1 R25P (Arg25Pro)

Signal-peptide missense variant altering TGF-β1 secretion levels, associated with cardiovascular inflammation, myocardial fibrosis, and coronary heart disease risk

See your personal result for TGFB1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TGF-β1 R25P — When the Body's Scar-Maker Works Overtime

Transforming growth factor beta 1 (TGF-β1) is one of the most versatile signaling molecules in the cardiovascular system — it can stabilize arterial plaques, suppress excessive inflammation, and regulate the repair of damaged heart muscle. But when TGF-β1 production tips too high or its signaling becomes dysregulated, the same molecule drives fibrosis, atherosclerosis progression, and myocardial remodeling after injury. The rs1800471 variant (R25P, Arg25Pro) sits in the signal peptide of the TGFB1 gene on chromosome 19q1311 chromosome 19q13
NC_000019.10:g.41352971C>G; TGFB1 encodes the inactive pre-pro-protein, cleaved to the active dimer, altering how efficiently the protein is threaded into the endoplasmic reticulum and ultimately secreted. The minor G allele (Pro25 on plus strand, coding C at position 915) influences TGF-β1 levels and has been linked to cardiovascular outcomes in multiple cohorts — though the direction and magnitude of risk are modest and population-dependent.

The Mechanism

The signal peptide is the N-terminal zip code that directs newly synthesized proteins into the secretory pathway. The Arg25Pro substitution changes a positively charged arginine to a neutral proline22 changes a positively charged arginine to a neutral proline
Proline introduces a rigid kink in the peptide backbone, potentially disrupting signal-peptide secondary structure and slowing translocation in this critical region. Functional studies show that different haplotypes formed by the codon 10 (rs1800470, L10P) and codon 25 (rs1800471, R25P) variants stratify individuals into high, intermediate, and low TGF-β1 producers33 high, intermediate, and low TGF-β1 producers
Leukocyte in-vitro assays measuring TGF-β1 in cell supernatants after stimulation classify genotype combinations into production categories. The GG coding genotype (homozygous Arg25, corresponding to plus-strand CC) is most commonly associated with highest TGF-β1 secretion capacity; the heterozygous state produces intermediate levels.

TGF-β1 has a dual and context-dependent role in the vasculature. At physiological levels it stabilizes atherosclerotic plaques44 stabilizes atherosclerotic plaques
TGF-β1 promotes smooth muscle cell contractility and fibrous cap formation, reducing plaque vulnerability to rupture and suppresses macrophage-mediated inflammation. At chronically elevated levels, it drives myocardial and vascular fibrosis55 drives myocardial and vascular fibrosis
Activates cardiac fibroblasts, increases collagen deposition, promotes atrial and ventricular remodeling — contributing to arrhythmia susceptibility, reduced cardiac compliance, and post-MI scarring.

The Evidence

The most comprehensive genetic evidence comes from a 2012 meta-analysis of 5 studies66 2012 meta-analysis of 5 studies
Qu et al., BMC Medical Genetics, 14,452 participants total that found minor allele (coding C, plus-strand G) carriers had a pooled OR of 1.16 (95% CI 1.02–1.32) for coronary heart disease. The heterozygous GC (coding, plus-strand CG) genotype conferred OR 1.15 (1.01–1.31) versus homozygous major allele carriers. However, statistical significance disappeared after Egger's test correction for publication bias, highlighting the modest and population-heterogeneous nature of the association.

Orthogonal evidence from fibrotic and electrophysiological studies is more consistent. A study of essential hypertensive patients77 study of essential hypertensive patients
Chen et al., Journal of Biomedical Science 2010, n=259 found the GG coding genotype was significantly overrepresented in patients with both hypertension and atrial fibrillation versus hypertension alone (P=0.009). GG coding carriers had the highest serum TGF-β1 levels among AF-positive subjects, with a 3.09-fold elevated AF risk in this context. Since atrial fibrosis is the primary substrate for atrial fibrillation, this provides a mechanistic link from the genotype through TGF-β1 to cardiac remodeling.

A Russian cohort study of MI patients88 Russian cohort study of MI patients
Contribution of TGFB1 to MI susceptibility, PMC3408705 found the GG coding genotype (high producer) significantly enriched in MI cases versus controls (OR 1.76, 95% CI 1.05–2.97, P=0.048). A study of TGFB1 and coronary heart disease with angiographic confirmation99 TGFB1 and coronary heart disease with angiographic confirmation
Lamblin et al., PMID 16543493 similarly linked codon 25 variants to MI in patients with confirmed CHD. The Rotterdam Study (n=5,972)1010 Rotterdam Study (n=5,972)
Verhoeven et al., Thrombosis and Haemostasis 2006 found no association with MI, illustrating the population-specific heterogeneity that characterizes this SNP.

Additional context: rs1800471 has been associated with hypertension and CKD progression1111 hypertension and CKD progression
Polish cohort, Archives of Medical Science 2013, consistent with the broader role of TGF-β1 in cardiovascular-renal fibrotic pathways.

Practical Actions

The cardiovascular implications of rs1800471 are primarily mediated through TGF-β1's effect on vascular inflammation and fibrosis. Carrying the minor G allele (plus strand) is associated with lower TGF-β1 production, and the heterozygous state shows modest CHD risk in aggregate analyses. Monitoring for early signs of cardiovascular disease and specific management of fibrosis-related risk factors (blood pressure, myocardial stiffness) are most relevant to this variant's biology.

Interactions

rs1800471 (codon 25) and rs1800470 (codon 10, L10P) are the two primary coding variants in the TGFB1 signal peptide. Together they form haplotypes that stratify TGF-β1 production capacity. The codon 10 high-producer T allele (rs1800470) and codon 25 G coding allele (rs1800471) combine into distinct HIGH, INTERMEDIATE, and LOW producer haplotypes. Carriers of both high-producer alleles across both codons show the strongest elevation in TGF-β1 secretion and likely the highest cumulative cardiovascular risk through fibrotic pathways. The rs1800469 promoter variant (-509 C/T) provides additional regulation of TGF-β1 transcription and should be interpreted alongside the coding variants.

Genotype Interpretations

What each possible genotype means for this variant.

CC Typical TGF-β1 Producer Normal

Normal TGF-β1 secretion — standard cardiovascular inflammatory balance

You carry two copies of the reference C allele (coding Arg25, GG in traditional codon-25 notation), the most common genotype with roughly 87% prevalence in European populations. This genotype is associated with normal to moderately high TGF-β1 secretion capacity — the baseline against which risk variants are compared. At physiological levels TGF-β1 helps stabilize arterial plaques, suppress excess vascular inflammation, and regulate cardiac repair. No variant-specific cardiovascular interventions are indicated beyond standard risk management.

CG Reduced TGF-β1 Producer Intermediate

Moderately reduced TGF-β1 production — modest cardiovascular risk signal

You carry one copy of the minor G allele (coding Pro25), present in approximately 12% of Europeans. Heterozygous carriers have intermediate TGF-β1 secretion levels. The 2012 CHD meta-analysis (5 studies, 14,452 participants) found CG carriers had OR 1.15 (95% CI 1.01–1.31) for coronary heart disease compared to CC homozygotes, though this signal was attenuated after publication-bias correction. The variant alters the TGF-β1 signal peptide, reducing secretion efficiency; reduced TGF-β1 may impair plaque stability and vascular anti-inflammatory control in some contexts.

GG Low TGF-β1 Producer Reduced

Low TGF-β1 production — elevated cardiovascular and fibrosis monitoring warranted

TGF-β1 stabilizes atherosclerotic plaques by maintaining fibrous cap integrity, suppressing macrophage inflammatory activity, and regulating smooth muscle cell behavior. Very low TGF-β1 secretion — as seen with the homozygous Pro25/Pro25 coding genotype — may result in plaques that are more lipid-rich and vulnerable to rupture, the proximate cause of most myocardial infarctions.

The broader TGF-β1 signaling axis also regulates: - Cardiac remodeling: Low TGF-β1 may impair adaptive repair after cardiac stress, while high TGF-β1 promotes fibrosis; the optimal window is narrow. - Blood pressure regulation: TGFB1 variants including rs1800471 have been associated with hypertension appearance in cohort studies, likely through effects on vascular wall remodeling. - Renal-cardiovascular axis: TGF-β1 is a key mediator of glomerular and tubular fibrosis; the rs1800471 polymorphism has been associated with CKD progression and hypertension onset.

At the GG homozygous state, co-carrier status for other TGFB1 variants (particularly rs1800470 codon 10) and lifestyle factors strongly modulate the phenotypic outcome. Blood pressure control is especially important since hypertension amplifies the cardiovascular risk from TGF-β1 dysregulation.